glp 1 agonists canada View of Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor 3 million Canadians use GLP-1
Description
doi: 10.2337/dci24-0003 [DOI] [PubMed] [Google Scholar] 133.Meissner WG, Remy P, Giordana C, et al

Modulation of Fatty Acid Metabolism by Glucagon in Man

Methods GLP-1 agonists included in the analysis were approved for treatment of obesity (Saxenda, Wegovy, Zepbound) and corresponding formulations that may potentially be used off-label for treatment of obesity (Mounjaro, Ozempic, Rybelsus, Victoza)

39 It was approved by the US FDA in 2014 to treat obesity (Saxenda , Novo Nordisk, Plainsboro, NJ, USA), after first being approved as a type 2 diabetes medication (Victoza , Novo Nordisk) in 2010 (Table 1)

Diabetes Research And Clinical Practice, 172 ,
